Axa PPP extends cancer cover to rejected NHS drug


Axa PPP has extended its cancer coverage to include the clinically effective prostate cancer drug rejected for the NHS because it is too expensive.

As COVER reported yesterday, the National Institute for Health and Clinical Excellence (Nice) announced in its draft guidance that abiraterone would not be made available for standard NHS use. It cited the estimated cost of at least £63,200 per quality-adjusted life year (QALY) as being too much for the NHS to bear despite it prolonging patients lives by around three months. The decision prompted the amendments from Axa PPP which said it would now join Bupa and WPA in including coverage for the drug. A report in the Guardian said the private medical insurance (PMI) provider had cha...

To continue reading this article...

Join Professional Adviser

  • Unlimited access to real-time news, industry insights and market intelligence.
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters.
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection.
  • Members-only access to the editor’s weekly Friday commentary
 Be the first to hear about our events and awards programmes.



Already a Professional Adviser member?


More on PMI


Bupa rolls out full mental health cover to individual market

Time limits removed

Adam Saville
clock 07 June 2019 • 1 min read

VitalityHealth launches 'comprehensive' mental health package

Unlimited CBT and counselling

Adam Saville
clock 07 February 2019 • 2 min read

April UK withdraws from UK health insurance market

'Existing PMI customers will require advice'

Adam Saville
clock 19 July 2018 • 1 min read